A new case report details a novel genetic mutation linked to drug resistance in a non-small cell lung cancer patient ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

MAIA Biotechnology, Inc. (NYSEAMERICAN: MAIA) disclosed information relating to its Phase 2 THIO-101 trial in advanced non-small cell lung cancer through a press release on February 4, 2025. According ...

In the latest study, researchers found the main genetic mutations in renal cell cancer, possibly by using artificial intelligence (AI). The scientists injected mRNA vaccine made against proteins ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European ...

In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve treatment outcomes for patients with high-risk early-stage triple-negative ...

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled "Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 ...

Here we present a case of a patient with stage IV CD-74-ROS1 fusion NSCLC discovered initially with RNA next generation sequencing (NGS) who acquired ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Hong Kong-listed Shanghai Henlius Biotech Inc, a subsidiary of Fosun Pharma, announced on Wednesday that its anti-PD-1 mAb, ...

As pet owners, we dread the day our companions show signs of illness, but a vet has explained everything you need to know.